CTSK Antibody - #DF6614

>>买3送1 进行中>>
(10)   (8)  
产品: CTSK 抗体
货号: DF6614
描述: Rabbit polyclonal antibody to CTSK
应用: WB IHC IF/ICC
反应: Human, Mouse, Rat
预测: Pig, Horse, Sheep, Dog
分子量: 39kDa; 37kD(Calculated).
蛋白号: P43235
RRID: AB_2838576

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
预测:
Pig(83%), Horse(83%), Sheep(83%), Dog(83%)
克隆:
Polyclonal
特异性:
CTSK Antibody detects endogenous levels of total CTSK.
RRID:
AB_2838576
引用格式: Affinity Biosciences Cat# DF6614, RRID:AB_2838576.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Cathepsin K; Cathepsin O; Cathepsin O1; Cathepsin O2; Cathepsin X; CATK_HUMAN; CTS02; Ctsk; CTSO; CTSO1; CTSO2; MGC23107; PKND; PYCD;

抗原和靶标

免疫原:
Uniprot:

P43235(CATK_HUMAN) >>Visit HPA database.

基因/基因ID:
CTSK(1513)
表达:
P43235 CATK_HUMAN:

Predominantly expressed in osteoclasts (bones) (PubMed:7805878). Expressed in thyroid epithelial cells (PubMed:11082042).

描述:
CTSK(cathepsin K), also named as CTSO, CTSO2, is a recently identified lysosomal cysteine proteinase. CTSK is synthesized as a proenzyme of 38 kDa and subsequently enters acidic lysosomal compartments, in which the propeptide is cleaved and transformed into an active enzyme and it may influence adipocyte differentiation through modifying extracellularmatrixcomponents(PMID:16912123). It is revealed both the 46-kDa cathepsin-K precursor and the 30-kDa mature form in mouse bone extracts(PMID:9811821). The high CTSK protein levels are only detected in primary cultured fibroblasts derived from normal and neoplastic breast tissue, where the 37- and 25-kDa bands to be detected correspond to pro- and mature proteins through western blot(PMID:18765527). The full length protein has a signal peptides with 15 amino acids and a propeptide with 99 amino acids. This antibody is specific to CTSK.
序列:
MWGLKVLLLPVVSFALYPEEILDTHWELWKKTHRKQYNNKVDEISRRLIWEKNLKYISIHNLEASLGVHTYELAMNHLGDMTSEEVVQKMTGLKVPLSHSRSNDTLYIPEWEGRAPDSVDYRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM

种属预测

种属预测:

score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。

Species
Results
Score
Pig
83
Horse
83
Sheep
83
Dog
83
Bovine
75
Rabbit
75
Zebrafish
57
Xenopus
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - P43235 作为底物

Site PTM Type Enzyme
C139 S-Nitrosylation
S246 Phosphorylation
S260 Phosphorylation

研究背景

功能:

Thiol protease involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Involved in the release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen.

细胞定位:

Lysosome. Secreted. Apical cell membrane>Peripheral membrane protein>Extracellular side.
Note: Localizes to the lumen of thyroid follicles and to the apical membrane of thyroid epithelial cells.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Predominantly expressed in osteoclasts (bones). Expressed in thyroid epithelial cells.

蛋白家族:

Belongs to the peptidase C1 family.

研究领域

· Cellular Processes > Transport and catabolism > Lysosome.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

文献引用

1). Ultrasmall PtAu2 nanoclusters activate endogenous anti-inflammatory and anti-oxidative systems to prevent inflammatory osteolysis. Theranostics (PubMed: 36793859) [IF=12.4]
2). Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis. Theranostics (PubMed: 35673565) [IF=12.4]

Application: IHC    Species: Mouse    Sample:

Figure 1 Histological assays for CTSK and integrin αv in atherosclerosis. (A and D) Typical immunofluorescence image of CTSK and integrin αv in mouse aorta, respectively. (B and E) IHC images of CTSK and integrin αv in mouse aorta, respectively (Designated regions indicated by red square frames in Figures are enlarged to show the details). (C and F) Quantitative IHC analysis of CTSK and integrin αv positive area percentage, respectively (n = 3). Ctrl: control; AS: atherosclerosis.
3). Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity. Frontiers in Pharmacology (PubMed: 36210855) [IF=5.6]
4). Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway. Aging-US (PubMed: 32381754) [IF=5.2]

Application: WB    Species: rat    Sample: bone marrow

Figure 4. |Y1R antagonist treatment promoted bone formation and inhibit bone resorption in OVX rats. (A) The Alizarin Red S (yellow arrow head) and TRAP staining (red arrow head) of bone tissues in groups. (B) Immunohistochemical analysis of bone tissue among groups for MMP9 and RUNX2 (x 400). (C, D) Western blotting results of MMP, RUNX2, Cath-K, OPG and RANKL expression in bone marrow from rat femurs. The data are expressed as the means ± SD (n = 6 in each group). ***P<0.001; ****P<0.0001 vs. SHAM, and #P<0.05; ####P<0.0001 vs. OVX by one-way ANOVA and Tukey’s post hoc test
5). A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer. European Journal of Pharmacology (PubMed: 31112710) [IF=5.0]

Application: WB    Species: human    Sample: MDA-MB-231 and SK-BR-3 cells

Fig. 5.| SM934-Testosterone suppressed Cathepsin K expression (A) Quantitative real-time PCR analyzed the expression level of Cathepsin K mRNA in MDA-MB231 and SK-BR-3 cells treated with different compounds. (B) Western blot was performed to analyze the expression level of Cathepsin K protein in MDA-MB-231 and SK-BR-3 cells treated with different compounds.
6). Oroxin B Attenuates Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Formation and Activity. Drug Design, Development and Therapy (PubMed: 34876805) [IF=4.8]

Application: WB    Species: Mouse    Sample:

Figure 4 OB abrogates RANKL‐associated NFATc1and c-fos transcription and downregulates osteoclast-related genes. (A) The RT‐qPCR assay detected the relative mRNA expression of osteoclastogenesis-associated marker genes, including NFATc1, c-fos, TRAP, Rank, cathepsin K and MMP9. (B) Western-blot analysis for OB’s effects on protein levels of NFATc1 and c-fos. (C) Western-blot analysis for OB’s effects on protein levels of MMP9 and cathepsin K. (D) Quantitative analysis of NFATc1 and c-fos. (E) Quantitative analysis of MMP9 and cathepsin K. (F) Immunofluorescence images for OB’s effects on protein expression of NFATc1. ns, no statistical significance
7). Schistosoma japonicum cystatin suppresses osteoclastogenesis via manipulating the NF‑κB signaling pathway. Molecular Medicine Reports (PubMed: 33576450) [IF=3.4]

Application: WB    Species:    Sample: RAW264.7 cells

Figure 4. |rSj‑Cys inhibits the expression of osteoclastogenesis‑related genes and proteins. RAW264.7 cells were co‑stimulated with M‑CSF (25 ng/ml) and RANKL (30 ng/ml) and then treated with or without rSj‑Cys (0.3 µM) for different time periods (24, 48 or 72 h). The expression levels of genes and proteins associated with osteoclast phenotype markers (CTSK, TRAP, ITGB3) and cell surface receptors of osteoclast precursors (RANK, OSCAR, TREM‑2)were determined by (A) reverse transcription‑quantitative PCR and (B) western blot analysis.
8). A Novel Rat Model of Patellofemoral Osteoarthritis Due to Patella Baja, or Low-Lying Patella. MEDICAL SCIENCE MONITOR (PubMed: 30979862) [IF=3.1]

Application: IHC    Species: rat    Sample: subchondral bone

Figure 9.| Photomicrographs of the immunohistochemistry for cathepsin K and osteoprotegerin (OPG) of the patella and trochlea induced by patellar ligament shortening (PLS) surgery in the rat model of patellofemoral joint osteoarthritis (PFJOA). (A) Representative immunohistochemical images of both cathepsin K and osteoprotegerin (OPG) in the subchondral bone.
9). Deletion of osteopontin in non-small cell lung cancer cells affects bone metabolism by regulating miR-34c/Notch1 axis: a clue to bone metastasis. European Journal of Histochemistry (PubMed: 37491944) [IF=2.0]

Application: WB    Species: Mouse    Sample: RAW264.7 cells

Figure 3.Deletion of osteopontin (OPN) inhibited the differentiation of osteoclasts. A) RANK-positive rate of RAW264.7 cells was detected by flow cytometry. B) The protein expressions of OCs markers Cathepsin K and CTR were detected by Western blot. C) The area of F-actin ring was evaluated by immunofluorescence staining.
10). Tanshinone I Mitigates Steroid-Induced Osteonecrosis of the Femoral Head and Activates the Nrf2 Signaling Pathway in Rats. Evidence-Based Complementary and Alternative Medicine (PubMed: 35111227)

Application: WB    Species: Rat    Sample:

Figure 3 TsI restrains osteoclastogenesis in the femoral heads of the MPS-induced SIONFH rat model. (a) TRAP activity in the serum. (b) Expression levels of CTSK and ACP5 in the femoral heads. ∗∗p < 0.01; ns, no significant. TRAP, tartrate-resistant acid phosphatase; CTSK, cathepsin K; ACP5, acid phosphatase 5.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.